Sangamo BioSciences | SGMO - Interest Expense On Debt


Sangamo BioSciences reported 97.56M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
Bayer EUR 675M 87M Dec/2025
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Cipla INR 170.3M 39M Jun/2026
Compugen USD 1.35M 399K Mar/2026
CSL USD 215M 111M Dec/2025
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Grifols EUR 156.07M 31.46M Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Merck USD 525M 46M Jun/2026
Novartis USD 462M 119M Jun/2026
Omeros USD 4.05M 5.16M Sep/2024
Pfizer USD 667M 4M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 287M 109M Jun/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025